Sanara MedTech (NASDAQ:SMTI) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of Sanara MedTech (NASDAQ:SMTI) from a buy rating to a hold rating in a report issued on Sunday.

SMTI has been the subject of several other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sanara MedTech in a report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Sanara MedTech in a report on Monday, January 26th. Finally, Zacks Research cut shares of Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $36.00.

Sanara MedTech Stock Performance

Shares of SMTI opened at $17.24 on Friday. The stock has a 50-day simple moving average of $19.49 and a 200-day simple moving average of $23.69. The company has a debt-to-equity ratio of 7.75, a quick ratio of 1.59 and a current ratio of 1.80. The stock has a market capitalization of $158.09 million, a PE ratio of -4.08 and a beta of 1.10. Sanara MedTech has a 1 year low of $16.05 and a 1 year high of $35.95.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings data on Tuesday, March 24th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.07). The company had revenue of $27.55 million for the quarter, compared to analyst estimates of $27.90 million. Sanara MedTech had a negative return on equity of 20.73% and a negative net margin of 36.42%. On average, analysts predict that Sanara MedTech will post -1.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sanara MedTech

Hedge funds have recently made changes to their positions in the company. Stonebridge Wealth Management LLC purchased a new stake in shares of Sanara MedTech in the 2nd quarter valued at about $3,397,000. Marshall Wace LLP boosted its position in shares of Sanara MedTech by 144.3% in the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock valued at $2,030,000 after purchasing an additional 42,237 shares during the period. Geode Capital Management LLC grew its stake in Sanara MedTech by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 79,049 shares of the company’s stock worth $1,846,000 after buying an additional 546 shares during the last quarter. Squarepoint Ops LLC grew its stake in Sanara MedTech by 56.0% during the 4th quarter. Squarepoint Ops LLC now owns 48,953 shares of the company’s stock worth $1,143,000 after buying an additional 17,570 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new position in Sanara MedTech during the second quarter worth approximately $382,000. Hedge funds and other institutional investors own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.